2 results
Approved WMOWill not start
To assess the pharmacokinetics and safety of naloxegol in paediatric patients ages > 6 months to < 18 years receiving treatment with opioids.
Approved WMOCompleted
Primary Objective** To compare the PFS of melflufen plus dexamethasone (Arm A) versus pomalidomide plus dexamethasone (Arm B) as assessed by the Independent Review Committee (IRC) according to the International Myeloma Working Group Uniform Response…